An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumours

Official Title

A Phase Ia/Ib, Open-Label, Multicentre, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumours

Summary:

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumours.

Trial Description

Primary Outcome:

• Percentage of Participants with Adverse Events

• Serum Concentration of XmAb24306
• Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
• Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1
• Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1
• ORR as Based on Radiographic Assessment by the Investigator Using Modified RECIST v1.1 for Immune-Based Therapeutics (iRECIST)
• DOR as Based on Radiographic Assessment by the Investigator Using iRECIST
• PFS as Based on Radiographic Assessment by the Investigator Using iRECIST
• Overall Survival (OS)

View this trial on ClinicalTrials.gov